Table: Towa Pharmaceutical -2020/21 parent results
May 14 (Reuters)-
Towa Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2021 Mar 31, 2020 Mar 31, 2022 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 115.35 107.65
(+7.1 pct) (+5.1 pct)
Operating 19.94 16.74
(+19.2 pct) (+5.9 pct)
Recurring 18.63 21.70
(-14.1 pct) (+14.4 pct)
Net 13.65 15.25
(-10.5 pct) (+12.1 pct)
EPS 277.39 yen 309.99 yen
EPS Diluted 265.95 yen 286.73 yen
Ann Div 44.00 yen 44.00 yen 51.00 yen
-Q2 Div 22.00 yen 22.00 yen 27.00 yen
-Q4 Div 22.00 yen 22.00 yen 24.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results